Indolium 1 Exerts Activity against Vemurafenib-Resistant Melanoma In Vivo
Indolium 1 Exerts Activity against Vemurafenib-Resistant Melanoma In Vivo
About this item
Full title
Author / Creator
Publisher
Switzerland: MDPI AG
Journal title
Language
English
Formats
Publication information
Publisher
Switzerland: MDPI AG
Subjects
More information
Scope and Contents
Contents
The development of targeted therapies (BRAF/MEK inhibitors) and immunotherapy have had a major impact on the treatment of melanoma. However, the majority of patients with advanced melanomas succumb to their disease. The mechanisms of resistance to both targeted therapies and immunotherapies are numerous and have been well-described. These include t...
Alternative Titles
Full title
Indolium 1 Exerts Activity against Vemurafenib-Resistant Melanoma In Vivo
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_0f54a91741a34b3c9113ce461af14dea
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_0f54a91741a34b3c9113ce461af14dea
Other Identifiers
ISSN
2076-3921
E-ISSN
2076-3921
DOI
10.3390/antiox11050798
